Literature DB >> 26036710

Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013.

Michael Bröker1, Stéphane Emonet, Cecilia Fazio, Susanne Jacobsson, Maria Koliou, Markku Kuusi, David Pace, Metka Paragi, Alexander Pysik, Maria João Simões, Anna Skoczynska, Paola Stefanelli, Maija Toropainen, Muhamed-Kheir Taha, Georgina Tzanakaki.   

Abstract

Neisseria meningitidis or meningococcus is divided into 12 distinct serogroups of which A, B, C, W, X, and Y are medically most important and cause health problems in different parts of the world. The epidemiology of N. meningitidis is unpredictable over time and across geographic regions. Globally, serogroup A has been prevalent in the African "meningitis belt" whereas serogroup B and C have predominated in Europe. In a paper published earlier in this journal (1) , an increase in serogroup Y invasive meningococcal disease (IMD) in some European countries was reported based on the epidemiological data for 2010, 2011 and 2012. Here, we report additional data from 30 European countries indicating that high or increased serogroup Y disease levels have continued in 2013 in certain regions of Europe. In the Western and Central Europe, there were no major changes in the proportion of serogroup Y IMD cases in 2013 compared to 2012. In the Scandinavian countries, proportion of serogroup Y disease remained high, ranging from 26% to 51% in 2013. This was in contrast to Baltic, Eastern and most Southern European countries, where the proportion of serogroup Y IMD was low similarly to previous years. For the last 2 decades, the mean age of patients affected by serogroup Y was 41 y for 7 countries from which data was available and 50% of cases were in patients aged 45 to 88 y. The age distribution of serogroup Y was bimodal and did not change significantly despite the increase of the total number and the proportion of serogroup Y IMD in some European regions.

Entities:  

Keywords:  Europe; IMD, Invasive meningococcal disease; Men, meningococcal.; Neisseria meningitidis; epidemiology; invasive meningococcal disease; meningococcal serogroup Y

Mesh:

Year:  2015        PMID: 26036710      PMCID: PMC4635851          DOI: 10.1080/21645515.2015.1051276

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  9 in total

Review 1.  Bexsero® chronicle.

Authors:  George Vernikos; Duccio Medini
Journal:  Pathog Glob Health       Date:  2014-10       Impact factor: 2.894

2.  Meningococcal serogroup Y emergence in Europe: high importance in some European regions in 2012.

Authors:  Michael Bröker; Suzana Bukovski; Davor Culic; Susanne Jacobsson; Maria Koliou; Markku Kuusi; Maria João Simões; Anna Skoczynska; Maija Toropainen; Muhamed-Keir Taha; Georgina Tzanakaki
Journal:  Hum Vaccin Immunother       Date:  2014-03-07       Impact factor: 3.452

3.  Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales.

Authors:  Shamez N Ladhani; Kazim Beebeejaun; Jay Lucidarme; Helen Campbell; Steve Gray; Ed Kaczmarski; Mary E Ramsay; Ray Borrow
Journal:  Clin Infect Dis       Date:  2014-11-10       Impact factor: 9.079

4.  Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy.

Authors:  Catherine A Jeppesen; Matthew D Snape; Hannah Robinson; Nicoletta Gossger; Tessa M John; Merryn Voysey; Shamez Ladhani; Ifeanyichukwu O Okike; Clarissa Oeser; Alison Kent; Jennifer Oliver; Pippa Taylor; Begonia Morales-Aza; Stuart C Clarke; Michelle Casey; Filipa Martins; Nicholas R E Kitchin; Annaliesa S Anderson; Hal Jones; Kathrin U Jansen; Joseph Eiden; Louise Pedneault; Paul T Heath; Adam Finn; Saul N Faust; Andrew J Pollard
Journal:  J Infect       Date:  2015-02-21       Impact factor: 6.072

5.  Meningococcal serogroup Y emergence in Europe: update 2011.

Authors:  Michael Bröker; Susanne Jacobsson; Markku Kuusi; David Pace; Maria J Simões; Anna Skoczynska; Muhamed-Kheir Taha; Maija Toropainen; Georgina Tzanakaki
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

6.  Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.

Authors:  Peter C Richmond; Helen S Marshall; Michael D Nissen; Qin Jiang; Kathrin U Jansen; Maria Garcés-Sánchez; Federico Martinón-Torres; Johannes Beeslaar; Leszek Szenborn; Jacek Wysocki; Joseph Eiden; Shannon L Harris; Thomas R Jones; John L Perez
Journal:  Lancet Infect Dis       Date:  2012-05-07       Impact factor: 25.071

7.  Whole genome sequencing to investigate the emergence of clonal complex 23 Neisseria meningitidis serogroup Y disease in the United States.

Authors:  Mary G Krauland; Julie C Dunning Hotopp; David R Riley; Sean C Daugherty; Jane W Marsh; Nancy E Messonnier; Leonard W Mayer; Hervé Tettelin; Lee H Harrison
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

8.  Secular trends in invasive meningococcal disease, Massachusetts, 1988-2011: what happened to invasive disease?

Authors:  A H Peruski; P Kludt; R S Patel; A DeMaria
Journal:  Epidemiol Infect       Date:  2014-12       Impact factor: 4.434

9.  Correlating epidemiologic trends with the genotypes causing meningococcal disease, Maryland.

Authors:  M Catherine McEllistrem; John A Kolano; Margaret A Pass; Dominique A Caugant; Aaron B Mendelsohn; Antonio Guilherme Fonseca Pacheco; Kathleen A Shutt; Jafar Razeq; Lee H Harrison
Journal:  Emerg Infect Dis       Date:  2004-03       Impact factor: 6.883

  9 in total
  23 in total

1.  Acquisition of Beta-Lactamase by Neisseria meningitidis through Possible Horizontal Gene Transfer.

Authors:  Eva Hong; Ala-Eddine Deghmane; Muhamed-Kheir Taha
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 2.  Epidemiology of invasive meningococcal disease in Greece, 2006-2016.

Authors:  Anastasia Flountzi; Theano Georgakopoulou; Sooria Balasegaram; Konstantinos Kesanopoulos; Athanasia Xirogianni; Anastasia Papandreou; Georgina Tzanakaki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-15       Impact factor: 3.267

3.  Serogroup Y Clonal Complex 23 Meningococcus in China Acquiring Penicillin Resistance from Commensal Neisseria lactamica Species.

Authors:  Youxing Shao; Mingliang Chen; Jiayuan Luo; Dan Li; Lingyue Yuan; Xiaoying Yang; Minggui Wang; Min Chen; Qinglan Guo
Journal:  Antimicrob Agents Chemother       Date:  2022-06-02       Impact factor: 5.938

Review 4.  Challenges and opportunities for meningococcal vaccination in the developing world.

Authors:  Rouba Shaker; Danielle Fayad; Ghassan Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2018-02-23       Impact factor: 3.452

5.  Bacterial agents causing meningitis during 2013-2014 in Turkey: A multi-center hospital-based prospective surveillance study.

Authors:  Mehmet Ceyhan; Yasemin Ozsurekci; Nezahat Gürler; Eda Karadag Oncel; Yıldız Camcioglu; Nuran Salman; Melda Celik; Melike Keser Emiroglu; Fatih Akin; Hasan Tezer; Aslinur Ozkaya Parlakay; Nilden Tuygun; Diyar Tamburaci; Ener Cagri Dinleyici; Adem Karbuz; Ünal Uluca; Emre Alhan; Ümmühan Çay; Zafer Kurugol; Nevin Hatipoğlu; Rengin Şiraneci; Tolga İnce; Gülnar Sensoy; Nursen Belet; Enes Coskun; Fatih Yilmaz; Mustafa Hacimustafaoglu; Solmaz Celebi; Ümit Celik; Metehan Ozen; Aybüke Akaslan; İlker Devrim; Necdet Kuyucu; Fatmanur Öz; Sefika Elmas Bozdemir; Ahu Kara
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

6.  Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database.

Authors:  Muhamed-Kheir Taha; Catherine Weil-Olivier; Stéphane Bouée; Corinne Emery; Gaëlle Nachbaur; Céline Pribil; Véronique Loncle-Provot
Journal:  Hum Vaccin Immunother       Date:  2021-01-15       Impact factor: 3.452

7.  Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines.

Authors:  Lidia Serra; Markus Knuf; Federico Martinón-Torres; Kevin Yi; Jamie Findlow
Journal:  Hum Vaccin Immunother       Date:  2021-02-19       Impact factor: 3.452

Review 8.  Routinely vaccinating adolescents against meningococcus: targeting transmission & disease.

Authors:  Volker Vetter; Roger Baxter; Gülhan Denizer; Marco A P Sáfadi; Sven-Arne Silfverdal; Andrew Vyse; Ray Borrow
Journal:  Expert Rev Vaccines       Date:  2016-03-04       Impact factor: 5.217

Review 9.  Impact of vaccination on meningococcal epidemiology.

Authors:  Paola Stefanelli; Giovanni Rezza
Journal:  Hum Vaccin Immunother       Date:  2015-10-29       Impact factor: 3.452

10.  Epidemiological and Molecular Characterization of Invasive Meningococcal Disease in Italy, 2008/09-2012/13.

Authors:  Arianna Neri; Patrizio Pezzotti; Cecilia Fazio; Paola Vacca; Fortunato Paolo D'Ancona; Maria Grazia Caporali; Paola Stefanelli
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.